Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINTRAVENOUSGeneric

SYNERCID

DALFOPRISTIN; QUINUPRISTIN

Standard Dose
350MG/VIAL;150MG/VIAL
Max Dose
Refer to approved labeling
Primary Use
Please see www.fda.gov/STIC for labeling requirements on susceptibility test interpretive criteria for systemic antibacterial and antifungal drugs. Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview SYNERCID is listed in Drugs@FDA under application 050748 (NDA).

Please see www.fda.gov/STIC for labeling requirements on susceptibility test interpretive criteria for systemic antibacterial and antifungal drugs.

Structured Monograph

Clinical summary

Approval overview SYNERCID is listed in Drugs@FDA under application 050748 (NDA). Please see www.fda.gov/STIC for labeling requirements on susceptibility test interpretive criteria for systemic antibacterial and antifungal drugs. Review priority: STANDARD Marketing status: Discontinued Active ingredient DALFOPRISTIN; QUINUPRISTIN Form and strength INJECTABLE;INTRAVENOUS - 350MG/VIAL;150MG/VIAL Sponsor KING PHARMS Submission history Latest submission status date: 2017-06-16 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.